国药现代：将持续推进战略发展规划，稳步提升经营业绩来提升公司价值

Group 1 - The company emphasizes the importance of addressing investor concerns by increasing cash dividends and establishing a three-year shareholder return plan starting in 2024 [2] - The company is committed to advancing its strategic development plan and steadily improving operational performance to enhance company value [2]